RxDoctor Payments Data

Pararajasingham Yogeswaran, MD

Interventional Cardiology · Erie, PANPI 1841210655

Payments from drug & device makers

$2,072in general payments, 2019–2025

Across 61 payments — averaging $33.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$709
  • Abiomed$339
  • E.r. Squibb & Sons, L.L.C.$251
  • Abbott$230
  • Boehringer Ingelheim$100
  • Shockwave Medical, Inc$90
  • plus $354 from 10 others

What the payments were for

  • Food & beverage$2,072100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,072 in reported general payments places this provider in the 15th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$127,099
Medicare patients
783
Services billed
1,529

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan219$258,201
EliquisApixaban229$214,780
Repatha SureclickEvolocumab186$132,206
XareltoRivaroxaban105$109,463
JardianceEmpagliflozin53$57,815
BrilintaTicagrelor54$49,079
Praluent PenAlirocumab52$37,181
Ranolazine ErRanolazine167$10,908
Ezetimibe341$5,880
Metoprolol Succinate501$5,740
Atorvastatin Calcium442$4,229
ClopidogrelClopidogrel Bisulfate352$3,768
Omega-3 Acid Ethyl Esters62$3,645
Isosorbide Mononitrate ErIsosorbide Mononitrate300$2,900
Amiodarone Hcl56$2,816

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$51$258,201219 claims
PfizerEliquis$44$214,780229 claims
Boehringer IngelheimJardiance$100$57,81553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Erie

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →